Abstract Number: LB16 • ACR Convergence 2025
Mepolizumab Reduces End-Organ Manifestations Compared with Standard of Care in Patients with EGPA and HES: A US Real-world Analysis
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are rare systemic diseases characterized by persistent eosinophilia and tissue infiltration, resulting in end-organ dysfunction…Abstract Number: 2338 • ACR Convergence 2025
Real-World Outcomes of Combined Tofacitinib and TNF Inhibitor Therapy in Refractory Inflammatory Arthritis: A Tertiary Care Experience from India
Background/Purpose: The use of combination biologic and targeted synthetic DMARDs remains controversial due to safety concerns, yet may offer benefit in refractory inflammatory arthritis. This…Abstract Number: 2054 • ACR Convergence 2025
A Changing Paradigm: Reassessing the Role of Muscle Biopsy in Idiopathic Inflammatory Myopathies in a Single-Center Cohort
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) encompass a heterogenous group of autoimmune diseases characterized by inflammation of muscle and other target organs. Muscle biopsy was historically…Abstract Number: 1721 • ACR Convergence 2025
Excess Mortality in SLE Is Concentrated in Lupus Nephritis and aPL-Positive Subsets: A population-based inception cohort study
Background/Purpose: Five-year survival in SLE has plateaued since the 1990s. Most epidemiologic studies pool all SLE phenotypes; It is possible that the excess mortality observed…Abstract Number: 1533 • ACR Convergence 2025
Belimumab Is Associated with Early Improvement in Disease Activity Measures Among Patients with Systemic Lupus Erythematosus in the US
Background/Purpose: Belimumab (BEL), a B-cell modulator mAb that selectively inhibits soluble B-lymphocyte stimulator and reduces autoreactive B cells that drive lupus disease activity, is approved…Abstract Number: 1220 • ACR Convergence 2025
Predictors of Progressive Pulmonary Fibrosis in Idiopathic Inflammatory Myopathies : a Retrospective Study of 502 Cases
Background/Purpose: Interstitial lung disease (ILD) in idiopathic inflammatory myopathies (IIM) causes worse prognosis. Some patients develop progressive pulmonary fibrosis (PPF) despite appropriate treatment. Identifying predictors…Abstract Number: 1038 • ACR Convergence 2025
Real-World Immunosuppressant Treatment Patterns in Lupus Nephritis: A Retrospective Claims Database Analysis in the United States
Background/Purpose: LN is a severe manifestation of SLE requiring intensive management. We aimed to characterize real-world treatment patterns in newly diagnosed patients with LN within…Abstract Number: 0544 • ACR Convergence 2025
Prevalence and Baseline Characteristics associated with Difficult-to-Manage Axial Spondyloarthritis in the DESIR Cohort
Background/Purpose: Despite a choice of multiple targeted DMARDs, with different modes of action (MoA), a number of patients with axial spondyloarthritis (axSpA) have failed several…Abstract Number: 0306 • ACR Convergence 2025
Direct Assessment of Intestinal Permeability as a Risk Factor for Multiple Joint Osteoarthritis in Community Cohorts of Humans and Pet Dogs
Background/Purpose: Increased intestinal permeability (IP) is common in chronic inflammatory diseases, and can be measured indirectly (e.g., with blood markers such as lipopolysaccharide, LPS), or…Abstract Number: 2606 • ACR Convergence 2025
The Impact of Social Media and Artificial Intelligence on Illness Perception and Treatment Adherence in Patients with Rheumatic Diseases
Background/Purpose: Social media (SM) and Artificial Intelligence (AI) are common sources of health information for patients with chronic diseases. Seeking medical information from unreliable sources…Abstract Number: 2331 • ACR Convergence 2025
Coping with Rheumatic Stressors in Axial Spondyloarthritis: Association with Patient Characteristics and Disease Phenotypes and Changes Over Time
Background/Purpose: To identify patient characteristics and disease phenotypes associated with coping strategies in axial spondyloarthritis (axSpA), and assess whether coping strategies change over time.Methods: Data…Abstract Number: 2045 • ACR Convergence 2025
Malignancy in Behçet’s Syndrome: A 24-Year Cohort Study In a Non-Endemicand Multiethnic Country
Background/Purpose: Behçet’s syndrome (BS) has been associated with an increased risk of malignancy, particularly in studies from endemic regions such as East Asia and the…Abstract Number: 1710 • ACR Convergence 2025
Defining sonographic enthesitis in psoriatic arthritis: Developing a data- and expert-driven definition for inflammatory enthesitis at the single enthesis level
Background/Purpose: Enthesitis affects 30–40% of PsA patients but remains difficult to diagnose due to overlap with non-specific entheseal pain. While OMERACT has standardized ultrasound (US)…Abstract Number: 1513 • ACR Convergence 2025
Race, Renal Failure, and Risk: A five-to-ten year retrospective cohort study of Racial differences in outcomes of patients with dialysis-dependent Lupus nephritis
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that disproportionately affects racial and ethnic minority populations, particularly Black/African American and Hispanic/Latino individuals. In…Abstract Number: 1180 • ACR Convergence 2025
Gender-Based Clinical Differences in Behçet’s Syndrome: Findings from a 24-Year Cohort in a Non-Endemic and Multiethnic Country
Background/Purpose: Behçet’s syndrome (BS) is a multisystemic inflammatory condition that affects both genders, although gender-related differences in disease manifestations may vary across regions. Studies report…
- 1
- 2
- 3
- …
- 38
- Next Page »